Patents by Inventor Xiaojing Michael Wang

Xiaojing Michael Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 2,5-heterocyclic derivatives
    Patent number: 7470701
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: December 30, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Xiaodong Lin, Alice Rico, Xiaojing Michael Wang, Yasheen Zhou, Ann B. Jefferson, Annette Walter
  • SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES
    Publication number: 20080255120
    Abstract: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Application
    Filed: May 29, 2008
    Publication date: October 16, 2008
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Xiaodong Lin, Alice Rico, Xiaojing Michael Wang, Yasheen Zhou, Ann B. Jefferson, Annette Walter
  • Imidazoquinoline Compounds
    Publication number: 20080213308
    Abstract: The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).
    Type: Application
    Filed: September 14, 2005
    Publication date: September 4, 2008
    Inventors: Nicholas Valiante, Feng Xu, Xiaodong Lin, Daniel Chu, Xiaojing Michael Wang